Simona Tavecchio
Overview
Explore the profile of Simona Tavecchio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors
Barei F, Calzari P, Valtellini L, Chiei Gallo A, Perego G, Tavecchio S, et al.
J Dermatolog Treat
. 2024 Oct;
35(1):2404718.
PMID: 39396818
Background: Atopic dermatitis (AD) profoundly impacts patients' lives, necessitating long-term systemic treatments. Methods: This retrospective study involved 709 severe AD patients receiving dupilumab. Drug survival (DS) was analyzed using Kaplan-Meier...
2.
Ferrucci S, Tavecchio S, Maronese C, Balato A, Di Brizzi E, Ortoncelli M, et al.
Clin Exp Dermatol
. 2024 Jun;
49(12):1561-1572.
PMID: 38860563
Background: The efficacy and safety of dupilumab in atopic dermatitis (AD) have been defined in clinical trials but limited real-world evidence on long-term treatment outcomes is currently available to inform...
3.
Ferrucci S, Tavecchio S, Ceresa A, Angileri L, Berti E, Marzano A, et al.
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610745
: Atopic Dermatitis (AD) is a prevalent inflammatory skin disease whose course is often complicated by the presence of concomitant anxiety and depressive disorders. Dupilumab has been demonstrated to be...
4.
Barei F, Zussino M, Tavecchio S, Angileri L, Rizzo A, Calzari P, et al.
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256950
Background: The main objective was to analyze patient-reported outcomes (PRO) trends over a four-year period in severe atopic dermatitis (AD) patients treated with dupilumab. Methods: data from 126 severe patients...
5.
Ferrucci S, Barei F, Tavecchio S, Marzano A, Zussino M, Naldi L, et al.
J Dermatolog Treat
. 2023 Nov;
34(1):2285243.
PMID: 37985495
No abstract available.
6.
Ferrucci S, Casazza G, Zussino M, Tavecchio S, Marzano A, Tedeschi M
J Clin Med
. 2023 Oct;
12(20).
PMID: 37892713
Efforts have been made to identify factors influencing clinical response in patients with atopic dermatitis (AD) treated with dupilumab. A retrospective single-center observational study was carried out by analyzing data...
7.
Ferrucci S, Tavecchio S, Nicolini G, Angileri L, Ceresa A, Del Tordello G, et al.
Int Clin Psychopharmacol
. 2023 Oct;
39(3):201-205.
PMID: 37781860
Atopic dermatitis (AD) is an inflammatory skin disease. Patients with AD are prone to develop anxiety and mood disorders. Aim of this study is to investigate if treatment with dupilumab...
8.
Dubini M, Benzecry V, Rivolta F, Sangalli A, Marzano A, Pravettoni V, et al.
Front Allergy
. 2023 Sep;
4:1223657.
PMID: 37753208
Introduction: Atopic dermatitis (AD) is considered a systemic type 2 immune driven disease, and it is associated to many atopic comorbidities including asthma. The aim of our study was to...
9.
Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan R, Bangert C, et al.
Clin Transl Allergy
. 2023 Sep;
13(9):e12299.
PMID: 37746794
Introduction: The integrated care pathways for atopic dermatitis (AD-ICPs) aim to bridge the gap between existing AD treatment evidence-based guidelines and expert opinion based on daily practice by offering a...
10.
Ferrucci S, Tavecchio S, Marzano A, Buffon S
Dermatol Ther (Heidelb)
. 2023 Apr;
13(5):1071-1081.
PMID: 37072648
Atopic dermatitis (AD) is a chronic or chronically relapsing inflammatory skin disease which results from a complex, multifaceted interaction between environmental factors in genetically predisposed patients. Epidermal barrier impairment, alteration...